Thackray Helen M.

SEC source: 0001127602-25-011136 · form4.xml · nonDerivative · entry 1

Thackray Helen M. · CIK 0001589725 · Chief R&D Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 377,318

F1 · shares: Represents shares withheld by the issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted Restricted Stock Units. This transaction does not represent a sale by the reporting person.

SEC source: 0001127602-24-029969 · form4.xml · derivative · entry 3

Thackray Helen M. · CIK 0001589725 · Chief R&D Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 260,950

Underlying: Common Stock · 260,950 shares

Expires 2034-12-19

F3 · derivative.exercise_date: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

SEC source: 0001127602-24-029969 · form4.xml · nonDerivative · entry 2

Thackray Helen M. · CIK 0001589725 · Chief R&D Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 384,843

F2 · shares: Represents shares withheld by the Issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted Restricted Stock Units. This transaction does not represent a sale by the Reporting Person.

SEC source: 0001127602-24-029969 · form4.xml · nonDerivative · entry 1

Thackray Helen M. · CIK 0001589725 · Chief R&D Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 390,939

F1 · shares: Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant.

SEC source: 0001127602-24-029566 · form4.xml · nonDerivative · entry 1

Thackray Helen M. · CIK 0001589725 · Chief R&D Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 264,989

F1 · shares: Represents shares withheld by the Issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted Restricted Stock Units. This transaction does not represent a sale by the Reporting Person.

SEC source: 0001127602-24-015371 · form4.xml · nonDerivative · entry 1

Thackray Helen M. · CIK 0001589725 · Chief R&D Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 272,139

F1 · price: The price in column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $5.84 to $5.86. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.

SEC source: 0001127602-24-011832 · form4.xml · nonDerivative · entry 1

Thackray Helen M. · CIK 0001589725 · Chief R&D Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 242,139

F1 · shares: Represents shares withheld by the issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted Restricted Stock Units. This transaction does not represent a sale by the reporting person.

SEC source: 0001104659-24-014717 · tm245865-14_4seq1.xml · derivative · entry 6

Thackray Helen M. · CIK 0001589725 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 19,597 shares

Expires 2033-06-14

F4 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.

F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.

F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.

SEC source: 0001104659-24-014717 · tm245865-14_4seq1.xml · derivative · entry 5

Thackray Helen M. · CIK 0001589725 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 32,066 shares

Expires 2032-06-15

F4 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.

F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.

F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.

SEC source: 0001104659-24-014717 · tm245865-14_4seq1.xml · derivative · entry 4

Thackray Helen M. · CIK 0001589725 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 44,000 shares

Expires 2031-09-22

F4 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.

F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.

F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.

SEC source: 0001104659-24-014717 · tm245865-14_4seq1.xml · derivative · entry 3

Thackray Helen M. · CIK 0001589725 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 40,932 shares

Expires not disclosed

F3 · derivative.exercise_price: Pursuant to the Merger Agreement, at the Effective Time, each deferred share unit ("DSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such DSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such DSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration.

F3 · kind: Pursuant to the Merger Agreement, at the Effective Time, each deferred share unit ("DSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such DSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such DSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration.

F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each deferred share unit ("DSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such DSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such DSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration.

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each deferred share unit ("DSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such DSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such DSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration.

F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each deferred share unit ("DSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such DSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such DSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration.

SEC source: 0001104659-24-014717 · tm245865-14_4seq1.xml · derivative · entry 2

Thackray Helen M. · CIK 0001589725 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 13,090 shares

Expires not disclosed

F2 · derivative.exercise_price: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration.

F2 · kind: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration.

F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration.

F2 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration.

SEC source: 0001104659-24-014717 · tm245865-14_4seq1.xml · nonDerivative · entry 1

Thackray Helen M. · CIK 0001589725 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated November 30, 2023, by and among the Issuer, AbbVie Inc., a Delaware corporation ("AbbVie"), Athene Subsidiary LLC, a Delaware limited liability company and wholly owned subsidiary of AbbVie ("Intermediate Sub"), and Athene Merger Sub Inc., a Massachusetts corporation and wholly owned subsidiary of Intermediate Sub ("Purchaser"), pursuant to which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation (the "Merger"). At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $.01 per share, of the Issuer (the "Common Stock"), that was issued and outstanding immediately prior to the Effective Time was converted into the right to receive an amount in cash equal to $31.26, without interest (the "Merger Consideration").

F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated November 30, 2023, by and among the Issuer, AbbVie Inc., a Delaware corporation ("AbbVie"), Athene Subsidiary LLC, a Delaware limited liability company and wholly owned subsidiary of AbbVie ("Intermediate Sub"), and Athene Merger Sub Inc., a Massachusetts corporation and wholly owned subsidiary of Intermediate Sub ("Purchaser"), pursuant to which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation (the "Merger"). At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $.01 per share, of the Issuer (the "Common Stock"), that was issued and outstanding immediately prior to the Effective Time was converted into the right to receive an amount in cash equal to $31.26, without interest (the "Merger Consideration").

SEC source: 0001415889-24-000372 · form4-01032024_100139.xml · nonDerivative · entry 1

Thackray Helen M. · CIK 0001589725 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,074

F1 · acquired: Shares of common stock issued pursuant to the Compensation Policy for Non-Employee Directors as amended June 14, 2023 in lieu of cash compensation for services performed for the quarter ended December 31, 2023.

SEC source: 0001127602-23-030189 · form4.xml · nonDerivative · entry 1

Thackray Helen M. · CIK 0001589725 · Chief R&D Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 249,664

F1 · shares: Represents shares withheld by the issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted Restricted Stock Units. This transaction does not represent a sale by the reporting person.

SEC source: 0001127602-23-029839 · form4.xml · derivative · entry 3

Thackray Helen M. · CIK 0001589725 · Chief R&D Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 238,000

Underlying: Common Stock · 238,000 shares

Expires 2033-12-14

F3 · derivative.exercise_date: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

SEC source: 0001127602-23-029839 · form4.xml · nonDerivative · entry 2

Thackray Helen M. · CIK 0001589725 · Chief R&D Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 255,244

F2 · shares: Represents shares withheld by the issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted Restricted Stock Units. This transaction does not represent a sale by the reporting person.

SEC source: 0001127602-23-029839 · form4.xml · nonDerivative · entry 1

Thackray Helen M. · CIK 0001589725 · Chief R&D Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 258,275

F1 · shares: Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant.

SEC source: 0001415889-23-013759 · form4-10022023_091016.xml · nonDerivative · entry 1

Thackray Helen M. · CIK 0001589725 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,822

F1 · acquired: Shares of common stock issued pursuant to the Compensation Policy for Non-Employee Directors as amended June 14, 2023 in lieu of cash compensation for services performed for the quarter ended September 30, 2023.

SEC source: 0001415889-23-010819 · form4-07052023_090742.xml · nonDerivative · entry 1

Thackray Helen M. · CIK 0001589725 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,350

F1 · acquired: Shares of common stock issued pursuant to the Compensation Policy for Non-Employee Directors as amended June 14, 2023 for services performed for the quarter ended June 30, 2023.

SEC source: 0001415889-23-009953 · form4-06162023_080610.xml · derivative · entry 2

Thackray Helen M. · CIK 0001589725 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,597

Underlying: Common Stock · 19,597 shares

Expires 2033-06-14

F3 · derivative.exercise_price: The stock options were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors, as amended, and the 2018 Employee, Director and Consultant Equity Incentive Plan, as amended.

F4 · derivative.exercise_date: The stock options vest ratably on each of 9/1/23, 12/1/23, 3/1/24, and 6/1/24, contingent upon the individual remaining a director as of each vesting date.

SEC source: 0001415889-23-009953 · form4-06162023_080610.xml · derivative · entry 1

Thackray Helen M. · CIK 0001589725 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,090

Underlying: Common Stock · 13,090 shares

Expires not disclosed

F1 · derivative.exercise_price: The restricted stock units ("RSUs") were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors, as amended, and the 2018 Employee, Director and Consultant Equity Incentive Plan, as amended. Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.

F1 · price: The restricted stock units ("RSUs") were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors, as amended, and the 2018 Employee, Director and Consultant Equity Incentive Plan, as amended. Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.

F2 · derivative.exercise_date: The restricted stock units vest on the one-year anniversary of the date of grant, contingent upon the individual remaining a director as of the vesting date.

F2 · derivative.expiration_date: The restricted stock units vest on the one-year anniversary of the date of grant, contingent upon the individual remaining a director as of the vesting date.

SEC source: 0001127602-23-012587 · form4.xml · nonDerivative · entry 1

Thackray Helen M. · CIK 0001589725 · Chief R&D Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 207,275

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2022 to cover tax withholding obligations in connection with the vesting of 25,000 Restricted Stock Units. The sale occurred automatically to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the reporting person.

F2 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $8.24 to $8.31. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

SEC source: 0001415889-23-006063 · form4-04042023_080459.xml · nonDerivative · entry 1

Thackray Helen M. · CIK 0001589725 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,953

F1 · acquired: Shares of common stock issued pursuant to the Compensation Policy for Non-Employee Directors as amended December 15, 2022 for services performed for the quarter ended March 31, 2023.

SEC source: 0001127602-22-028082 · form4.xml · derivative · entry 2

Thackray Helen M. · CIK 0001589725 · Chief R&D Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 238,000

Underlying: Common Stock · 238,000 shares

Expires 2032-12-19

F2 · derivative.exercise_date: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

SEC source: 0001127602-22-028082 · form4.xml · nonDerivative · entry 1

Thackray Helen M. · CIK 0001589725 · Chief R&D Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 214,275

F1 · shares: Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant.

SEC source: 0001127602-22-027887 · form4.xml · nonDerivative · entry 1

Thackray Helen M. · CIK 0001589725 · Chief R&D Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 133,275

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2022 to cover tax withholding obligations in connection with the vesting of 11,000 Restricted Stock Units. The sale occurred automatically to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

F2 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $10.50 to $11.33. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

SEC source: 0001415889-22-006706 · form4-06172022_010634.xml · derivative · entry 2

Thackray Helen M. · CIK 0001589725 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,066

Underlying: Common Stock · 32,066 shares

Expires 2032-06-15

F4 · derivative.exercise_date: The stock options vest ratably over a one-year period in quarterly increments beginning on September 1, 2022, contingent upon the individual remaining a director as of each vesting date.

SEC source: 0001415889-22-006706 · form4-06172022_010634.xml · derivative · entry 1

Thackray Helen M. · CIK 0001589725 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,932

Underlying: Common Stock · 10,932 shares

Expires not disclosed

F1 · derivative.exercise_price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis.

F1 · price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis.

F2 · derivative.exercise_date: The deferred share units vest ratably over a one-year period in quarterly increments beginning on September 1, 2022, contingent upon the individual remaining a director as of each vesting date.

F3 · derivative.exercise_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors.

F3 · derivative.expiration_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors.

F3 · derivative.underlying: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors.

SEC source: 0001127602-22-011188 · form4.xml · nonDerivative · entry 1

Thackray Helen M. · CIK 0001589725 · Chief R&D Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 136,400

F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2022.

F2 · shares: Shares sold to satisfy the reporting person's withholding obligations upon the vesting of restricted stock units granted in 2021.

F3 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $16.09 to $16.27. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

SEC source: 0001127602-21-031130 · form4.xml · derivative · entry 2

Thackray Helen M. · CIK 0001589725 · Chief R&D Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 205,000

Underlying: Common Stock · 205,000 shares

Expires 2031-12-14

F2 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

SEC source: 0001127602-21-031130 · form4.xml · nonDerivative · entry 1

Thackray Helen M. · CIK 0001589725 · Chief R&D Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 144,000

F1 · shares: Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant.

SEC source: 0001179110-21-008903 · edgar.xml · derivative · entry 2

Thackray Helen M. · CIK 0001589725 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,000

Underlying: Common Stock · 44,000 shares

Expires 2031-09-22

F4 · derivative.exercise_date: The stock options vest ratably over a three-year period in quarterly increments beginning on December 1, 2021, contingent upon the individual remaining a director as of each vesting date.

SEC source: 0001179110-21-008903 · edgar.xml · derivative · entry 1

Thackray Helen M. · CIK 0001589725 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires not disclosed

F1 · derivative.exercise_price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis.

F1 · price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis.

F3 · derivative.exercise_date: The deferred share units vest ratably over a three-year period in quarterly increments beginning on December 1, 2021, contingent upon the individual remaining a director as of each vesting date.

F2 · derivative.exercise_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors.

F2 · derivative.expiration_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors.

F2 · derivative.underlying: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors.

SEC source: 0001127602-21-012780 · form4.xml · derivative · entry 2

Thackray Helen M. · CIK 0001589725 · Director · Chief R&D Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 400,000

Underlying: Common Stock · 400,000 shares

Expires 2031-03-31

F2 · shares: Options become exercisable at a rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

SEC source: 0001127602-21-012780 · form4.xml · nonDerivative · entry 1

Thackray Helen M. · CIK 0001589725 · Director · Chief R&D Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

F1 · shares: Award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant.

SEC source: 0001209191-21-004845 · doc4.xml · derivative · entry 2

Thackray Helen M. · CIK 0001589725 · SVP Clinical Development, CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,000

Underlying: Common Stock · 69,000 shares

Expires 2031-01-19

F3 · derivative.exercise_date: 25% of the shares underlying this option vest on January 20, 2022 and the balance of the shares vest in a series of 36 successive equal monthly installments thereafter, subject to the reporting person's continuous service as of each such vesting date.

SEC source: 0001209191-21-004845 · doc4.xml · nonDerivative · entry 1

Thackray Helen M. · CIK 0001589725 · SVP Clinical Development, CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 183,115

F1 · security: The security represents restricted stock units granted to the reporting person. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.

F2 · shares: 25% of these restricted stock units vest on each of January 20, 2022, 2023, 2024 and 2025, subject to the reporting person's continuous service as of each such vesting date.

SEC source: 0001127602-20-016584 · form4.xml · derivative · entry 1

Thackray Helen M. · CIK 0001589725 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2030-05-12

F1 · security: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan.

SEC source: 0001209191-20-004818 · doc4.xml · derivative · entry 1

Thackray Helen M. · CIK 0001589725 · SVP Clinical Development, CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 120,000

Underlying: Common Stock · 120,000 shares

Expires 2030-01-21

F1 · derivative.exercise_date: One-fourth of the shares underlying this option vest on January 22, 2021 and the balance of the shares vest in a series of 36 successive equal monthly installments thereafter, subject to the reporting person's continuous service as of each such vesting date.

SEC source: 0001127602-19-029012 · form4.xml · derivative · entry 1

Thackray Helen M. · CIK 0001589725 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2029-09-20

F1 · shares: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Amended and Restated Stock Incentive Plan.

SEC source: 0001209191-19-004823 · doc4.xml · derivative · entry 1

Thackray Helen M. · CIK 0001589725 · SVP Clinical Development, CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2029-01-16

F1 · derivative.exercise_date: One-fourth of the shares underlying this option vest on January 17, 2020 and the balance of the shares vest in a series of 36 successive equal monthly installments thereafter, subject to the reporting person's continuous service as of each such vesting date.

SEC source: 0001209191-18-003392 · doc4.xml · derivative · entry 1

Thackray Helen M. · CIK 0001589725 · SVP Clinical Development, CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2028-01-09

F1 · derivative.exercise_date: One-fourth of the shares underlying this option vest on January 10, 2019 and the balance of the shares vest in a series of 36 successive equal monthly installments thereafter, subject to the reporting person's continuous service as of each such vesting date.

SEC source: 0001209191-17-065185 · doc4.xml · nonDerivative · entry 1

Thackray Helen M. · CIK 0001589725 · SVP Clinical Development, CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 148,615

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b-5 trading plan adopted by the reporting person on June 19, 2017.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001209191-17-053214 · doc4.xml · nonDerivative · entry 1

Thackray Helen M. · CIK 0001589725 · SVP Clinical Development, CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,615

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b-5 trading plan adopted by the reporting person on June 19, 2017.

SEC source: 0001209191-17-036114 · doc4.xml · nonDerivative · entry 1

Thackray Helen M. · CIK 0001589725 · SVP Clinical Development, CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 152,615

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b-5 trading plan adopted by the reporting person on May 31, 2016.

SEC source: 0001209191-17-034534 · doc4.xml · nonDerivative · entry 1

Thackray Helen M. · CIK 0001589725 · SVP Clinical Development, CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 154,615

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 31, 2016.

SEC source: 0001209191-17-001651 · doc4.xml · derivative · entry 1

Thackray Helen M. · CIK 0001589725 · SVP Clinical Development, CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2027-01-03

F1 · derivative.exercise_date: One-fourth of the shares underlying this option vest on January 4, 2018 and the balance of the shares vest in a series of 36 successive equal monthly installments thereafter, subject to the reporting person's continuous service as of each such vesting date.

SEC source: 0001209191-16-144211 · doc4.xml · nonDerivative · entry 2

Thackray Helen M. · CIK 0001589725 · VP Clinical Development, CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 156,615

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 31, 2016.

SEC source: 0001209191-16-144211 · doc4.xml · nonDerivative · entry 1

Thackray Helen M. · CIK 0001589725 · VP Clinical Development, CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 156,715

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 31, 2016.